IGFBP-4，完整（大鼠和小鼠）ELISA-IGFBP-4, Intact (Rat and Mouse) ELISA代理/參數/廠家-ELISA試劑盒-艾美捷科技有限公司

PRODUCT CENTER

ELISA試劑盒

產品中心

當前位置：首頁 > 產品中心 > 免疫學產品 > ELISA試劑盒

中文名稱: IGFBP-4，完整（大鼠和小鼠）ELISA

英文名字: IGFBP-4, Intact (Rat and Mouse) ELISA

供應商: Ansh Labs

產品貨號: AL-1025

產品報價: ￥詢價/96wellmicrotiter

產品說明書: 點擊查看

購買方式: 90%產品中國有現貨庫存。銀行轉賬、電匯、支票、現金，在線支付寶及網銀支付，或直接與我們電話聯系400-6800-868

產品新聞

背景資料: Insulin‐like growth factor‐binding protein‐4 is a member of the insulin‐like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type‐I domain. The cDNA for human IGFBP‐4 encodes a 258‐residue protein that is processed, by removal of the signal sequence, to a mature protein of 237 residues (25.6 kDa) with a single asparagine‐linked glycosylation site(1). Although various cell types when in culture secrete both glycosylated (28‐29 kDa) and nonglycosylated (24‐25 kDa) forms of IGFBP‐4, the nonglycosylated is typically the most abundant in normal human blood (2, 3).
n
n
n
nIGFBP‐4 is unique among the six IGFBPs in having two extra cysteine residues in the variable L‐domain and may be responsible for the distinctive biological functions of IGFBP‐4 (4). Although the exact functional role for serum IGFBP‐4 is not absolutely clear, in vitro studies have shown that IGFBP‐4 inhibits IGF activity in bone cells and other cell types. IGFBP‐4 has been reported to inhibit IGF‐I‐ and IGF‐II‐induced cell proliferation of embryonic chick calvaria cells and MC3T3‐E1 mouse osteoblasts (5, 6), IGF‐I‐ and IGF‐II stimulated DNA synthesis in a variety of cell types.(3)
n
n
n
nProteolysis is a major regulatory mechanism of IGFBP‐4 functions. An IGF dependent IGFBP‐4‐specific protease was first reported in the media conditioned by both human and sheep dermal fibroblasts. This protease was later identified as pregnancy‐associated plasma protein‐A (PAPP‐A). It was shown that recombinant PAPP‐A is an active protease able to cleave IGFBP‐4 at a single site, between M135/K136. IGFBP‐4 cleavage by PAPP‐A is possible only in case when IGFBP is complexed with IGF. PAPP‐A also cleaves IGFBP‐5 between S143/K144, but in this case the presence of IGF is not required.
n
n
n
nSeveral studies have shown that concentration of PAPP‐A in blood of patients with acute coronary syndrome (ACS) is higher than in blood of patients with stable coronary artery disease or control subjects. PAPP‐A has been suggested as a marker of cardiovascular diseases associated with coronary artery blood clotting, such as unstable angina and myocardial infarction (MI) (7‐14). It was hypothesized that in atherosclerotic plaques PAPP‐A expressed by activated smooth muscles cells could function as an active enzyme cleaving IGFBP‐4 complexed with IGF, thus enhancing IGF bioavailability. The IGF system might contribute to the atherosclerotic plaque development, destabilization, and rupture leading to acute coronary events (15). It was shown that IGFBP‐4 is expressed by different cells of tumor origin, such as lung adenocarcinoma, non‐small‐cell lung cancer, breast cancer, colon carcinoma, follicular thyroid carcinoma, gastric cancer, glioma, hepatoma, myeloma, neuroblastoma, osteosarcoma and prostate cancer. In vitro and in vivo studies suggest that IGFBP‐4 plays an important role in the growth regulation of a variety of tumors, possibly by inhibiting autocrine IGF actions. Regulation of IGF bioavailability may play a crucial role in tumor growth and development (13). The measurements of IGFBP‐4 along with PAPP‐A enzyme activity could be of higher clinical value than just PAPP‐A measurements alone since PAPP‐A concentration in blood is affected by heparin injections. The concentration of PAPP‐A, total IGFBP‐4 and intact IGFBP‐4 in biological fluid can be measured accurately using immunoassay methods (picoPAPP‐A ELISA, AL‐101; Total IGFBP‐4 ELISA, AL‐126; and Intact IGFBP‐4 ELISA, AL‐128 respectively). The ratio of total to Intact IGFBP‐4 concentration measured in individual subjects over time may help normalizes the IGFBP‐4 variability between subjects and also increase the detection of increased PAPP‐A activity in MI subjects. The immunoassay methods designed for the measurement of total and Intact IGFBP‐4 in patient samples could be of practical value for the diagnosis or prediction of various pathologies including ACS and cancer.
n
n
n
nReferences:
n1. La Tour D, Mohan S, Linkhart T A, Baylink D J, Strong D D. Inhibitory insulin-like growth factor binding protein: cloning, complete sequence, and physiologic regulation. Mol Endocrinol. 1990; 4:1806-1814.
n2. Baxter R C, Martin J L. Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog in Growth Factor Res. 1989; 1:49-68.
n3. Rechler M M., Insulin-like growth factor binding proteins. Vitam Horm. 1993; pp. 471-114.
n4. Zhou R, Diehl D, Hoeflich A, Lahm H, Wolf E., IGF-binding protein-4: biochemical characteristics and functional consequences. Journal of Endocrinology 2003; 178: 177-193.
n5. Mohan S, Bautista C, Wergedal J, Baylink D J. Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell conditioned medium: a potential local regulator of IGF action. Proc Nat Acad Sci USA. 1989; 86:8338-8342.
n6. Mohan S, Nakao Y, Honda Y, et al., Studies on the molecular mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem. 1995; 270:20424-20431.
n7. Qin Q, Wittfooth S, Pettersson K. Measurement and clinical significance of circulating PAPP-A in ACS patients. Clin Chim Acta. 2007;380:59-67. 8. Iversen KK, Teisner AS, Teisner B, et al. Pregnancy Associated Plasma Protein A, a Novel, Quick, and Sensitive marker in ST-Elevation Myocardial Infarction. Am J Cardiol. 2008;101:1389-1394.
n9. Lund J, Qin Q, Ilva T, et al. Pregnancy-associated plasma protein A: A biomarker in acute ST-elevation myocardial infarction (STEMI). Annals of Medicine. 2006;38:221-228.
n10. Elesber AA, Lerman A, et al. Pregnancy associated plasma protein-A and risk stratification of patients presenting with chest pain in the emergency department. Int J Cardiol. 2007;117:365-369.
n11. Heeschen C, Dimmeler S, et al. Pregnancy-Associated Plasma Protein-A Levels in Patients With Acute Coronary Syndromes. JACC. 2005;45(2):229-237.
n12. Lund J, Qin Q, Ilva T, et al. Circulating Pregnancy-Associated Plasma Protein A Predeicts Outcome in Patients With Acute Coronary Syndrome but No Troponin I Elevation. Circulation. 2003;108:1924-1926.
n13. Bayes-Genis A, Conover CA, et al. Pregnancy-Associated Plasma Protein A as a Marker of Acute Coronary Syndromes. NEJM. 2001;345(14):1022-1029.

產品描述: The Rat/Mouse IGFBP-4 enzyme linked immunosorbent assay (ELISA) kit provides materials for the quantitative measurement of IGFBP-4 in mouse and rat samples.

產品特點

保存建議: Store at 2 to 8°C until expiration date.

其他: Ansh labs是開發和生產免疫檢測試劑盒和定制生物技術檢測產領創者，總部位于美國休斯敦，公司產品遍及全球80多個國家。公司于2011年成立，核心團隊來自于Diagnostic system laboratory，專注于女性健康和激素檢測領域近40年，擁有全球領先的核心技術，以及多年經驗生物技術研發經驗的科學家團隊，產品覆蓋生殖健康，高危妊娠，腫瘤，糖尿病等多個疾病領域，圍繞最新的免疫分析技術，多種蛋白和單克隆抗體，如AMH，BMP-15, Follistatin, GDF-9, IGF-I, IGF-II, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, Inhibin Alpha, Inhibin ?A, Inhibin ?B, MBP, PAPP-A, PAPP-A2 and Vitamin D.等幾十余種試劑產品，也同時涵蓋小鼠，大鼠，狗，羊，牛等靈長類多個物種的獨特的物種特異性的試劑。 Ansh labs 坐落于美國德克薩斯州，是目前世界上唯一能提供TGF-β超家族所有成員的檢測公司，也是最早專注激素類產品研究和新型免疫檢測技術的先驅者。優勢產品涉及TGF-β super family、AMH/抑制素B(human/animal)、full panel IGFs、以及最完整的胰高血糖素系列。